Could an iron scavenger slow ALS?
NCT ID NCT02164253
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether deferiprone, a drug that removes excess iron, could safely slow the progression of ALS. Researchers gave the drug to 23 adults with ALS for several months. The goal was to see if reducing iron buildup in the brain might protect nerve cells and delay worsening of symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
deferiprone (an iron-removing drug)
What this could lead to
If it works, this could point toward a treatment that slows ALS progression by reducing excess iron in the brain.
What could go wrong
This is a small, early-phase pilot study with only 23 participants, so results may not apply to all ALS patients. The drug also carries risks like low white blood cell counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS (AMYOTROPHIC LATERAL SCLEROSIS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Roger Salengro, CHRU de Lille
Lille, 59000, France